Health ❯Healthcare ❯Pharmaceuticals ❯Drug Development

Obesity Treatment

Pharmaceuticals Regulations Patient Care Drug Safety Drug Development Weight Loss Drugs Sales Growth Hormones Obesity Patient Outcomes

Novo Nordisk’s CagriSema Shows Greater Weight Loss at Lower Doses

Results unveiled at the ADA meeting suggest that a flexible dosing regimen could optimize weight-loss outcomes for many patients.

Novo Nordisk Revises 2025 Outlook as FDA Crackdown and Competition Reshape Wegovy Market

Roche and Zealand Partner in $5.3 Billion Deal for Obesity Drug Development